Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL JAMES DOWNING

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1639159346
CMS profile
300554
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$327.48

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $327.48 15

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL JAMES DOWNING

NPI 1639159346 · CMS profile ID 300554

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $327.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $15.5112/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585003 CMS
Neurocrine Biosciences, Inc. $18.1411/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693124787 CMS
Indivior Inc. $16.0410/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775213 CMS
Alkermes, Inc. $12.1409/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585005 CMS
Alkermes, Inc. $14.0608/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585001 CMS
Janssen Pharmaceuticals, Inc $19.5708/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658527621 CMS
Indivior Inc. $12.0707/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775211 CMS
JAZZ PHARMACEUTICALS INC. $12.7007/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684174127 CMS
Allergan Inc. $17.5207/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271099 CMS
Indivior Inc. $20.1306/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775209 CMS
Takeda Pharmaceuticals U.S.A., Inc. $99.4705/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682109013 CMS
Lundbeck LLC $12.3804/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684293419 CMS
Janssen Pharmaceuticals, Inc $25.0203/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658527615 CMS
Alkermes, Inc. $18.5803/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686584999 CMS
Allergan Inc. $14.1501/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271096 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 15
PY2020 $163.49 9
PY2021 $551.28 27
PY2022 $399.89 22
PY2023 $626.73 20
PY2024 $647.99 23
PY2025 $847.36 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $914,450.61 88
PY2024 Recipient $2,949.66 2
PY2024 Principal investigator $1,362,460.91 98
PY2023 Recipient $59,611.81 14
PY2023 Principal investigator $997,596.68 181
PY2022 Principal investigator $897,046.39 115
PY2021 Principal investigator $714,455.57 113
PY2020 Principal investigator $1,352,717.69 219
PY2019 Recipient $157,177.13 20
PY2019 Principal investigator $1,373,636.72 268

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

195 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $498.25 12/31/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998415021
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 12/29/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311829
Recipient PFIZER INC. $1,748.00 12/14/2023 Covered Recipient Physician A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1045942543
Recipient PFIZER INC. $3,178.70 12/14/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046050875
Principal investigator 1 Sumitomo Pharma America, Inc. $1,951.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312555
Principal investigator 1 Sumitomo Pharma America, Inc. $2,345.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312567
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312577
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312589
Principal investigator 1 Sumitomo Pharma America, Inc. $2,666.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312601
Principal investigator 1 Sumitomo Pharma America, Inc. $3,380.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312611
Principal investigator 1 Sumitomo Pharma America, Inc. $4,216.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312621
Principal investigator 1 Sumitomo Pharma America, Inc. $5,322.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312631
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312643
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312653
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312663
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312675
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312685
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312695
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312707
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312717
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312729
Principal investigator 1 Sumitomo Pharma America, Inc. $10,716.00 12/11/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312739
Principal investigator 1 Sumitomo Pharma America, Inc. $4.00 12/04/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312959
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 11/30/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311819
Principal investigator 1 PFIZER INC. $2,201.24 11/22/2023 Non-covered Recipient Entity
1
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046177805
Principal investigator 1 PFIZER INC. $8,545.25 11/16/2023 Non-covered Recipient Entity
1
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046053685
Principal investigator 1 PFIZER INC. $14,624.00 11/16/2023 Non-covered Recipient Entity
1
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046065595
Principal investigator 1 Sumitomo Pharma America, Inc. $2,345.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312241
Principal investigator 1 Sumitomo Pharma America, Inc. $2,345.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312251
Principal investigator 1 Sumitomo Pharma America, Inc. $2,345.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312261
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312269
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312283
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312293
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312303
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312315
Principal investigator 1 Sumitomo Pharma America, Inc. $2,666.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312327
Principal investigator 1 Sumitomo Pharma America, Inc. $2,666.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312335
Principal investigator 1 Sumitomo Pharma America, Inc. $2,666.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312345
Principal investigator 1 Sumitomo Pharma America, Inc. $3,380.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312355
Principal investigator 1 Sumitomo Pharma America, Inc. $5,322.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312367
Principal investigator 1 Sumitomo Pharma America, Inc. $5,322.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312377
Principal investigator 1 Sumitomo Pharma America, Inc. $5,322.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312387
Principal investigator 1 Sumitomo Pharma America, Inc. $5,322.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312397
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312411
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312421
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312431
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312441
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312451
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312461
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312473
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312483
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312493
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312503
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312515
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312525
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312535
Principal investigator 1 Sumitomo Pharma America, Inc. $6,408.90 11/15/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312545
Principal investigator 1 Sumitomo Pharma America, Inc. $23.16 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312815
Principal investigator 1 Sumitomo Pharma America, Inc. $27.64 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312825
Principal investigator 1 Sumitomo Pharma America, Inc. $40.72 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312835
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312843
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312853
Principal investigator 1 Sumitomo Pharma America, Inc. $50.55 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312863
Principal investigator 1 Sumitomo Pharma America, Inc. $50.90 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312875
Principal investigator 1 Sumitomo Pharma America, Inc. $55.28 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312883
Principal investigator 1 Sumitomo Pharma America, Inc. $67.40 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312893
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312905
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312915
Principal investigator 1 Sumitomo Pharma America, Inc. $81.44 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312927
Principal investigator 1 Sumitomo Pharma America, Inc. $138.20 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312935
Principal investigator 1 Sumitomo Pharma America, Inc. $207.30 11/02/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312947
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 10/31/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311807
Recipient PFIZER INC. $1,242.60 10/19/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046303927
Principal investigator 1 Sumitomo Pharma America, Inc. $1,877.94 10/18/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312211
Principal investigator 1 Sumitomo Pharma America, Inc. $2,000.00 10/18/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312221
Principal investigator 1 Sumitomo Pharma America, Inc. $2,500.00 10/18/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312231
Principal investigator 1 Sumitomo Pharma America, Inc. $95.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311901
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311911
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311921
Principal investigator 1 Sumitomo Pharma America, Inc. $2,477.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311931
Principal investigator 1 Sumitomo Pharma America, Inc. $2,666.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311943
Principal investigator 1 Sumitomo Pharma America, Inc. $2,666.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311953
Principal investigator 1 Sumitomo Pharma America, Inc. $2,666.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311963
Principal investigator 1 Sumitomo Pharma America, Inc. $2,666.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311975
Principal investigator 1 Sumitomo Pharma America, Inc. $3,380.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311983
Principal investigator 1 Sumitomo Pharma America, Inc. $3,380.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311993
Principal investigator 1 Sumitomo Pharma America, Inc. $3,380.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312003
Principal investigator 1 Sumitomo Pharma America, Inc. $4,216.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312015
Principal investigator 1 Sumitomo Pharma America, Inc. $5,322.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312027
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312037
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312047
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312061
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312071
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312081
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312091
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312103
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312113
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312125
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312135
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312147
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312155
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312167
Principal investigator 1 Sumitomo Pharma America, Inc. $5,901.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312177
Principal investigator 1 Sumitomo Pharma America, Inc. $6,468.60 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312187
Principal investigator 1 Sumitomo Pharma America, Inc. $7,720.00 10/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312199
Recipient PFIZER INC. $12,792.70 10/12/2023 Covered Recipient Physician A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1045893929
Recipient PFIZER INC. $1,242.60 10/05/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046191355
Principal investigator 1 Sumitomo Pharma America, Inc. $30.54 10/03/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312783
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 10/03/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312793
Principal investigator 1 Sumitomo Pharma America, Inc. $82.92 10/03/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312805
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 09/29/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311797
Principal investigator 1 ABBVIE INC. $1,300.00 09/27/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998401321
Principal investigator 1 ABBVIE INC. $6,571.00 09/27/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998401323
Principal investigator 1 ABBVIE INC. $460.00 09/26/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998401201
Principal investigator 1 ABBVIE INC. $6,000.00 09/26/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998401203
Principal investigator 1 ABBVIE INC. $500.00 09/26/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998401205
Recipient PFIZER INC. $8,116.02 09/26/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046086727
Recipient PFIZER INC. $7,896.40 09/21/2023 Covered Recipient Physician A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1045978967
Recipient PFIZER INC. $3,418.27 09/14/2023 Covered Recipient Physician A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046014689
Recipient PFIZER INC. $2,000.00 09/14/2023 Covered Recipient Physician A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046180639
Principal investigator 1 Sumitomo Pharma America, Inc. $27,481.50 09/13/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311891
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 09/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312763
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 09/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312773
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 08/31/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311787
Recipient PFIZER INC. $7,147.71 08/30/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046301891
Principal investigator 1 Sage Therapeutics, Inc. $37,231.56 08/28/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 1012242025
Principal investigator 1 Sumitomo Pharma America, Inc. $10,044.00 08/14/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311881
Principal investigator 1 Sumitomo Pharma America, Inc. $31.67 08/10/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311859
Principal investigator 1 Sumitomo Pharma America, Inc. $47.51 08/10/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311869
Recipient PFIZER INC. $2,852.85 08/03/2023 Covered Recipient Physician A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046086709
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 07/31/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311777
Principal investigator 1 PFIZER INC. $7,131.65 07/20/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046303079
Principal investigator 1 PFIZER INC. $8,733.34 07/13/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046097015
Principal investigator 1 Sumitomo Pharma America, Inc. $10,044.00 07/12/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311849
Principal investigator 1 Sumitomo Pharma America, Inc. $82.92 07/11/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030312749
Principal investigator 1 Sumitomo Pharma America, Inc. $31.67 07/04/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030311839
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 06/30/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339363
Principal investigator 1 PFIZER INC. $20,578.90 06/22/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1045999517
Principal investigator 1 Sumitomo Pharma America, Inc. $25,110.00 06/09/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339399
Principal investigator 1 PFIZER INC. $1,242.60 06/08/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046250151
Principal investigator 1 Sumitomo Pharma America, Inc. $50.90 06/01/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339531
Principal investigator 1 Sumitomo Pharma America, Inc. $50.90 06/01/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339537
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 06/01/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339543
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 06/01/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339549
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 06/01/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339557
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 05/31/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339357
Principal investigator 1 Sumitomo Pharma America, Inc. $5,022.00 05/12/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339393
Principal investigator 1 ABBVIE INC. $4,878.50 05/04/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998380949
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $146,214.85 05/04/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PoCC study in patients with PTSD No dispute reported 06/30/2026 1022142869
Recipient PFIZER INC. $1,162.80 05/04/2023 Covered Recipient Physician A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046344779
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 04/28/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339351
Recipient PFIZER INC. $5,948.90 04/26/2023 Covered Recipient Physician A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046346437
Recipient PFIZER INC. $864.26 04/06/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046096999
Principal investigator 1 ABBVIE INC. $24,794.50 04/05/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998376579
Principal investigator 1 Sumitomo Pharma America, Inc. $2,521.00 04/05/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339381
Principal investigator 1 Sumitomo Pharma America, Inc. $10,685.00 04/05/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339387
Principal investigator 1 Sumitomo Pharma America, Inc. $4.80 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339405
Principal investigator 1 Sumitomo Pharma America, Inc. $6.60 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339413
Principal investigator 1 Sumitomo Pharma America, Inc. $10.18 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339419
Principal investigator 1 Sumitomo Pharma America, Inc. $10.18 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339425
Principal investigator 1 Sumitomo Pharma America, Inc. $12.00 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339431
Principal investigator 1 Sumitomo Pharma America, Inc. $13.82 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339437
Principal investigator 1 Sumitomo Pharma America, Inc. $13.82 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339443
Principal investigator 1 Sumitomo Pharma America, Inc. $16.84 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339449
Principal investigator 1 Sumitomo Pharma America, Inc. $23.16 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339455
Principal investigator 1 Sumitomo Pharma America, Inc. $27.64 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339461
Principal investigator 1 Sumitomo Pharma America, Inc. $27.64 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339467
Principal investigator 1 Sumitomo Pharma America, Inc. $30.54 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339475
Principal investigator 1 Sumitomo Pharma America, Inc. $33.84 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339481
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339487
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339493
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339499
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339505
Principal investigator 1 Sumitomo Pharma America, Inc. $41.46 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339511
Principal investigator 1 Sumitomo Pharma America, Inc. $78.10 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339517
Principal investigator 1 Sumitomo Pharma America, Inc. $337.00 04/05/2023 Non-covered Recipient Entity
FutureSearch Trial Dallas
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339523
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 03/31/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339345
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $10,745.45 03/23/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046316431
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $21,118.00 03/23/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTIVE THERAPY IN ADULT SUBJECTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1014042223
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5.70 03/17/2023 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
PoCC study in patients with PTSD No dispute reported 06/30/2026 1022135465
Principal investigator 1 ABBVIE INC. $13,356.00 03/09/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998373239
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $3,193.75 03/09/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046322269
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $9,613.58 03/01/2023 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
PoCC study in patients with PTSD No dispute reported 06/30/2026 1007439325
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 02/28/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339339
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,166.98 02/16/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1045949053
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,045.35 02/16/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046014663
Principal investigator 1 Sage Therapeutics, Inc. $133,416.30 02/15/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder No dispute reported 06/30/2026 1012242011
Principal investigator 1 Sumitomo Pharma America, Inc. $25.00 02/14/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339369
Principal investigator 1 Sumitomo Pharma America, Inc. $95.01 02/14/2023 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder No dispute reported 06/30/2026 1030339375
Principal investigator 1 ABBVIE INC. $12,576.00 02/02/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998368433
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $9,405.86 01/26/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046323231
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,187.36 01/26/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1053188655
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $4,387.10 01/19/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1046009005
Principal investigator 1 ABBVIE INC. $20,793.50 01/11/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998364795
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,750.00 01/09/2023 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 1053188271